CTXR
Citius Pharmaceuticals, Inc.Company Information
- Company Name
- Citius Pharmaceuticals, Inc.
- CIK
- CIK0001506251
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CTXR: Nasdaq
- Fiscal Year End
- September 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CTXR
SEC filing data through
Insider Sentiment
- Last purchase
- 2019-09-27
- Last sale
- —
- Shares purchased (TTM)
- 4,087,795
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,339,746
- Shares outstanding
- 26,169,589
- Ownership
- 5.12%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -22.22%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 17 | 5 | 8 | 4 | 6 | 0 | 1 | 3 | 18 | 13 | 20 | 26 | ||||||
| Accounts Receivable Net Current | 1 | 1 | 4 | - | - | - | - | - | - | - | - | - | ||||||
| Inventory Net | 23 | 23 | 23 | 22 | 17 | 15 | 14 | 8 | - | - | - | - | ||||||
| Prepaid Expense Current | 3 | 3 | 4 | 1 | 1 | 3 | 3 | 3 | 10 | 9 | 8 | 8 | ||||||
| Inventory Gross | - | - | - | - | - | - | - | 8 | - | - | - | - | ||||||
| Assets Current | 43 | 32 | 38 | 28 | 25 | 18 | 18 | 14 | 28 | 22 | 28 | 34 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deposits Assets | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
Other Assets | ||||||||||||||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | ||||||
| Deferred Costs | - | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Goodwill | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | ||||||
| Other Assets | - | - | - | - | - | - | - | - | - | - | 69 | 69 | ||||||
| Other Assets Noncurrent | 98 | 100 | 102 | 102 | 102 | 102 | 102 | 102 | - | - | - | 69 | ||||||
| Assets | 142 | 133 | 140 | 131 | 128 | 121 | 121 | 117 | 97 | 91 | 97 | 104 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 8 | 9 | 11 | 14 | 10 | 9 | 7 | 5 | 2 | 3 | 3 | 3 | ||||||
| Accrued Liabilities Current | 26 | 24 | 5 | 4 | 9 | 9 | 6 | 0 | 1 | 0 | 0 | 0 | ||||||
| Employee Related Liabilities Current | 2 | 4 | 3 | 3 | 4 | 3 | 3 | 2 | 2 | 1 | 2 | 2 | ||||||
| Notes Payable Current | - | - | 1 | 1 | 1 | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 52 | 55 | 38 | 45 | 52 | 50 | 45 | 36 | 4 | 4 | 6 | 6 | ||||||
| Deferred Income Tax Liabilities Net | 8 | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | ||||||
| Long Term Notes Payable | 6 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 66 | 63 | 47 | 53 | 60 | 58 | 52 | 43 | 11 | 11 | 12 | 12 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 344 | 330 | 327 | 306 | 296 | 283 | 277 | 271 | 276 | 259 | 256 | 253 | ||||||
| Retained Earnings Accumulated Deficit | -277 | -268 | -247 | -239 | -231 | -222 | -211 | -201 | -191 | -180 | -171 | -162 | ||||||
| Stockholders Equity | 67 | 69 | 93 | 68 | 65 | 64 | 65 | 70 | 86 | 80 | 85 | 91 | ||||||
| Minority Interest | 9 | 8 | 14 | 10 | 3 | 3 | 4 | 4 | 1 | 1 | 1 | 1 | ||||||
| Liabilities And Stockholders Equity | 142 | 133 | 140 | 131 | 128 | 121 | 121 | 117 | 97 | 91 | 97 | 104 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 16 | 16 | 16 | 400 | 400 | 400 | 16 | ||||||
| Common Stock Shares Issued | 27 | 22 | 22 | 18 | 14 | 9 | 8 | 7 | 7 | 6 | 6 | 6 | ||||||
| Shares Outstanding | 27 | 22 | 22 | 18 | 14 | 9 | 8 | 7 | 7 | 6 | 6 | 6 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCitius Pharmaceuticals, Inc. (CTXR) — SEC Financial Statements & Analysis
Citius Pharmaceuticals, Inc. (CTXR) is a pharmaceutical preparations company, incorporated in NV. Citius Pharmaceuticals, Inc. trades on Nasdaq as: CTXR. Citius Pharmaceuticals, Inc. (CTXR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Citius Pharmaceuticals, Inc. carries a market cap of $15.83M, a P/E ratio of -0.32x, a P/B ratio of 0.24x, a P/S ratio of 2.23x, an enterprise value of $5.24M, and an EV/EBITDA multiple of -0.09x. On profitability, it posts an operating margin of -863.92%, a net margin of -695.20%, a Return on Equity (ROE) of -75.03%, a Return on Assets (ROA) of -36.60%, and a Return on Invested Capital (ROIC) of -105.72%. Per share, it reports EPS of $-1.89, diluted EPS of $-1.89, free cash flow per share of $-1.52, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 16.44% year-over-year and EPS growth of -51.02% year-over-year. On the balance sheet, it maintains a current ratio of 0.84x, a quick ratio of 0.34x, working capital of $-8.32M, a debt-to-equity ratio of 1.00x, a debt ratio of 0.47, an interest coverage ratio of -119.00x, free cash flow of $-39.87M (TTM), and net debt of $-10.60M. Figures sourced from SEC EDGAR.
- Market Cap
- $15.83M
- P/E TTM
- -0.32x
- EPS TTM
- $-1.89
- P/B TTM
- 0.24x
- ROE TTM
- -75.03%
- ROA TTM
- -36.60%
- Debt To Equity
- 1.00x
- Free Cash Flow TTM
- $-39.87M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Citius Pharmaceuticals, Inc. in?
Citius Pharmaceuticals, Inc. (CTXR) operates in the Pharmaceutical Preparations industry.
What exchange does CTXR trade on?
Citius Pharmaceuticals, Inc. (CTXR) trades on the Nasdaq.
Where is Citius Pharmaceuticals, Inc. incorporated?
Citius Pharmaceuticals, Inc. is incorporated in NV.
When was Citius Pharmaceuticals, Inc. (CTXR)'s most recent SEC filing?
Citius Pharmaceuticals, Inc. (CTXR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is CTXR's market cap?
Citius Pharmaceuticals, Inc. (CTXR) has a market capitalization of $15.83M as of 2026-06-30.
What is CTXR's EPS (earnings per share)?
Citius Pharmaceuticals, Inc. (CTXR)'s trailing twelve month EPS is $-1.89 as of 2026-06-30.
What is CTXR's ROE (return on equity)?
Citius Pharmaceuticals, Inc. (CTXR)'s trailing twelve month Return on Equity (ROE) is -75.03% as of 2026-06-30.
What is CTXR's ROA (return on assets)?
Citius Pharmaceuticals, Inc. (CTXR)'s trailing twelve month Return on Assets (ROA) is -36.60% as of 2026-06-30.
What is CTXR's ROIC (return on invested capital)?
Citius Pharmaceuticals, Inc. (CTXR)'s trailing twelve month Return on Invested Capital (ROIC) is -105.72% as of 2026-06-30.
What is CTXR's EV/EBITDA?
Citius Pharmaceuticals, Inc. (CTXR)'s trailing twelve month EV/EBITDA is -0.09x as of 2026-06-30.